Stuart Schrader, DO
Internal Medicine · Oklahoma City, OKNPI 1336173491
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 787 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 8.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,320, 2.2 times the $1,036 reported in 2019. Among internal medicine clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 787 payments — averaging $15.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$923
- AstraZeneca$867
- Amgen$782
- Bayer$713
- Novo Nordisk$625
- plus $7K from 54 others
Across 4 payments — averaging $4149.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Exact Sciences$17K
What the payments were for
- Food & beverage$11,75198%
- Education$1962%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,947 in reported general payments places this provider in the 95th percentile of 840 internal medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 74 | $86,204 |
| JardianceEmpagliflozin | 68 | $79,530 |
| RybelsusSemaglutide | 38 | $68,167 |
| OzempicSemaglutide | 44 | $64,919 |
| KerendiaFinerenone | 35 | $46,914 |
| FarxigaDapagliflozin Propanediol | 31 | $35,589 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 13 | $26,843 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 26 | $22,032 |
| EliquisApixaban | 33 | $21,902 |
| Repatha SureclickEvolocumab | 18 | $16,422 |
| JanuviaSitagliptin Phosphate | 11 | $13,046 |
| QuliptaAtogepant | 11 | $11,827 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $9,606 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $8,960 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $8,068 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $625 | $133,08682 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $203 | $87,15779 claims |
| Lilly USA, LLCMounjaro | $923 | $86,20474 claims |
| BayerKerendia | $713 | $46,91435 claims |
| AstraZenecaFarxiga | $867 | $35,58931 claims |
| MerckJanumet Xr, Januvia | $202 | $35,07837 claims |
| PfizerEliquis | $527 | $21,90233 claims |
| GSKBreo Ellipta, Anoro Ellipta | $425 | $17,02835 claims |
| AbbVieQulipta | $1,033 | $11,82711 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $91 | $9,60612 claims |
| Almatica Pharma LLCSertraline Hcl | $27 | $1,31537 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 840 internal medicine providers in Oklahoma.
Other internal medicine in Oklahoma City
- Ryan MorganOklahoma City$235K
- Ali JafryOklahoma City$33K
- Samid FarooquiOklahoma City$20K
- Dale BratzlerOklahoma City$17K
- Karen ChopraOklahoma City$16K
- Charlsie RecordOklahoma City$14K
- Jeannette KelleyOklahoma City$14K
- Zain Ul Abideen AsadOklahoma City$14K
- Patrick GarrisonOklahoma City$10K
- Alisha SolomonOklahoma City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.